{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T22:34:17Z","timestamp":1794090857188,"version":"4.8.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"38","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.vaccine.2023.07.045","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T15:18:30Z","timestamp":1690816710000},"page":"5614-5621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults"],"prefix":"10.1016","volume":"41","author":[{"given":"Bhagwat","family":"Gunale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9855-6984","authenticated-orcid":false,"given":"Nicholas","family":"Farinola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Yeolekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5980-8536","authenticated-orcid":false,"given":"Shubham","family":"Shrivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus S.","family":"Poonawalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev M.","family":"Dhere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidya","family":"Arankalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhilesh","family":"Chandra\u00a0Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Mehla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad S.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2023.07.045_b0005","doi-asserted-by":"crossref","first-page":"16055","DOI":"10.1038\/nrdp.2016.55","article-title":"Dengue infection","volume":"18","author":"Guzman","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1016\/j.vaccine.2023.07.045_b0010","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.aogh.2015.02.006","article-title":"The burden of dengue and chikungunya worldwide: implications for the southern United States and California","volume":"80","author":"Fredericks","year":"2014","journal-title":"Ann Glob Health"},{"key":"10.1016\/j.vaccine.2023.07.045_b0015","unstructured":"Dengue and severe dengue: WHO Fact Sheet. Available at: http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dengue-and-severe-dengue. Date 17 March 2023. Accessed on: 26 May 2023."},{"issue":"12 Suppl","key":"10.1016\/j.vaccine.2023.07.045_b0020","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/nrmicro2460","article-title":"Dengue: a continuing global threat","volume":"8","author":"Guzman","year":"2010","journal-title":"Nat Rev Microbiol"},{"issue":"12","key":"10.1016\/j.vaccine.2023.07.045_b0025","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1056\/NEJMoa1503877","article-title":"Symptomatic dengue in children in 10 Asian and Latin American Countries","volume":"374","author":"L'Azou","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.vaccine.2023.07.045_b0030","doi-asserted-by":"crossref","first-page":"455","DOI":"10.6061\/clinics\/2016(08)08","article-title":"Age and regional differences in clinical presentation and risk of hospitalization for dengue in Brazil, 2000\u20132014","volume":"71","author":"Burattini","year":"2016","journal-title":"Clinics (Sao Paulo)"},{"issue":"1","key":"10.1016\/j.vaccine.2023.07.045_b0035","first-page":"102","article-title":"Mortality among Hospitalized Dengue Patients with Comorbidities in Mexico, Brazil, and Colombia","volume":"105","author":"Macias","year":"2021","journal-title":"Am J Trop Med Hyg"},{"issue":"7446","key":"10.1016\/j.vaccine.2023.07.045_b0040","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.vaccine.2023.07.045_b0045","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1473-3099(16)00026-8","article-title":"The global burden of dengue: an analysis from the Global Burden of Disease Study 2013","volume":"16","author":"Stanaway","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.07.045_b0050","unstructured":"Dengue Cases and Deaths in the Country since 2015. https:\/\/nvbdcp.gov.in\/index4.php?lang=1&level=0&linkid=431&lid=3715. Accessed on 02 August 2022."},{"issue":"8","key":"10.1016\/j.vaccine.2023.07.045_b0055","doi-asserted-by":"crossref","first-page":"e1065","DOI":"10.1016\/S2214-109X(19)30250-5","article-title":"Burden of dengue infection in India, 2017: a cross-sectional population based serosurvey","volume":"7","author":"Murhekar","year":"2019","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2023.07.045_b0060","unstructured":"https:\/\/www.takeda.com\/newsroom\/newsreleases\/2022\/takedas-qdenga-dengue-tetravalent-vaccine-live-attenuated-approved-for-use-in-european-union\/ Date accessed 07 Jan 2023."},{"issue":"10","key":"10.1016\/j.vaccine.2023.07.045_b0065","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1080\/21645515.2019.1658503","article-title":"A review of Dengvaxia\u00ae: development to deployment","volume":"15","author":"Thomas","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"9951","key":"10.1016\/j.vaccine.2023.07.045_b0070","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2023.07.045_b0075","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.vaccine.2023.07.045_b0080","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2023.07.045_b0085","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/cid\/ciab864","article-title":"Three-year efficacy and safety of Takeda's dengue vaccine candidate (TAK-003)","volume":"75","author":"Rivera","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.07.045_b0090","unstructured":"https:\/\/www.takeda.com\/siteassets\/system\/newsroom\/2022\/qdenga\/ema-combined-h-5155-en.pdf Date accessed 22 May 2023."},{"key":"10.1016\/j.vaccine.2023.07.045_b0095","unstructured":"https:\/\/butantan.gov.br\/noticias\/butantan's-dengue-vaccine-has-79.6-efficacy-partial-results-from-2-year-follow-up-show Date accessed 07 Jan 2023."},{"key":"10.1016\/j.vaccine.2023.07.045_b0100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/vim.2006.19.10","article-title":"Development of a live attenuated dengue virus vaccine using reverse genetics","volume":"19","author":"Blaney","year":"2006","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2023.07.045_b0105","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4161\/hv.2.6.3494","article-title":"rDEN2\/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults","volume":"2","author":"Durbin","year":"2006","journal-title":"Hum Vaccin"},{"issue":"6","key":"10.1016\/j.vaccine.2023.07.045_b0110","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/infdis\/jis936","article-title":"A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial","volume":"207","author":"Durbin","year":"2013","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2023.07.045_b0115","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/infdis\/jiv082","article-title":"Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, Flavivirus-Naive Adults","volume":"212","author":"Kirkpatrick","year":"2015","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2023.07.045_b0120","doi-asserted-by":"crossref","first-page":"e0005584","DOI":"10.1371\/journal.pntd.0005584","article-title":"In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination","volume":"11","author":"Whitehead","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2023.07.045_b0125","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s41467-021-21384-0","article-title":"A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans","volume":"12","author":"Nivarthi","year":"2021","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.vaccine.2023.07.045_b0130","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(20)30023-2","article-title":"Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine BUTANTAN-DV in adults in brazil: A two-step, double-blind, randomised placebo-controlled phase 2 trial","volume":"20","author":"Kallas","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2023.07.045_b0135","doi-asserted-by":"crossref","first-page":"2046960","DOI":"10.1080\/21645515.2022.2046960","article-title":"A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-na\u00efve and flavivirus-experienced healthy adults","volume":"18","author":"Russell","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"330","key":"10.1016\/j.vaccine.2023.07.045_b0140","doi-asserted-by":"crossref","first-page":"330ra36","DOI":"10.1126\/scitranslmed.aaf1517","article-title":"The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model","volume":"8","author":"Kirkpatrick","year":"2016","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/j.vaccine.2023.07.045_b0145","doi-asserted-by":"crossref","first-page":"e0006657","DOI":"10.1371\/journal.pntd.0006657","article-title":"Stratified sero-prevalence revealed overall high disease burden of dengue but suboptimal immunity in younger age groups in Pune, India","volume":"12","author":"Mishra","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2023.07.045_b0150","unstructured":"https:\/\/www.globalpointofcare.abbott\/en\/product-details\/bioline-dengue-duo-ns1-ag-ab-combo.html Date accessed 26 May 2023."},{"issue":"11","key":"10.1016\/j.vaccine.2023.07.045_b0155","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3389\/fimmu.2020.00334","article-title":"Cross-reactive immunity among flaviviruses","volume":"26","author":"Rathore","year":"2020","journal-title":"Front Immunol"},{"issue":"24","key":"10.1016\/j.vaccine.2023.07.045_b0160","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1016\/j.vaccine.2018.02.062","article-title":"Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines","volume":"36","author":"Vannice","year":"2018","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2023.07.045_b0165","article-title":"Antibody-dependent enhancement: A challenge for developing a safe dengue vaccine","volume":"22","author":"Shukla","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2023.07.045_b0170","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.07.045_b0175","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.coviro.2020.09.005","article-title":"Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003\/TV005","volume":"43","author":"Durbin","year":"2020","journal-title":"Curr Opin Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2023.07.045_b0180","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/infdis\/jix314","article-title":"Replication and excretion of the live attenuated tetravalent dengue vaccine CYD-TDV in a flavivirus-naive adult population: Assessment of vaccine viremia and virus shedding","volume":"216","author":"Torresi","year":"2017","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2023.07.045_b0185","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.tmaid.2010.05.005","article-title":"The viruses of Australia and the risk to tourists","volume":"9","author":"Smith","year":"2011","journal-title":"Travel Med Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23008769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23008769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:29:28Z","timestamp":1759404568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23008769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":37,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0264410X23008769"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.07.045","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.07.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}